Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Diabetic mice kept normal blood sugar until the transplant was removed. The study lasted over 11 months.

Century Therapeutics Presents CNTY-813 Nonclinical Data At EASD 2026

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (NASDAQ:IPSC)

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet

Century Therapeutics stock extends strong run as IPSC jumps over 700 percent in 12 months

Century Therapeutics (IPSC) exec sale covers RSU taxes

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Century Therapeutics posts $34.6 million Q2 loss as cash runway reaches 2029

Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC

Will Century Therapeutics (NASDAQ:IPSC) Spend Its Cash Wisely?

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation

Century Therapeutics Reports First Quarter Financial Results and Business Updates